title: Differences in viral kinetics between genotypes 1 and 3 of hepatitis C virus and between cirrhotic and non-cirrhotic patients during antiviral therapy.
abstract: OBJECTIVE
  To evaluate the impact of hepatitis C virus (HCV) infection with genotype 1 or 3 and the presence or absence of liver cirrhosis (LC) in the early viral kinetics response to treatment.
  
  
  METHODS
  Naive patients (n = 46) treated with interferon-alpha (IFN-alpha) and ribavirin and followed up with frequent early HCV-RNA determinations were analysed. Patients were infected with genotype 1 (n = 28, 7 with LC) or 3 (n = 18, 5 with LC).
  
  
  RESULTS
  The first phase decline was larger in genotype 3 patients than in genotype 1 patients (1.72 vs 0.95 log IU/mL, P < 0.001). The second phase slope decline was also larger in genotype 3 patients than in genotype 1 patients (0.87 vs 0.15 log/wk, P < 0.001). Differences were found in both cirrhotic and non-cirrhotic patients. Genotype 1 cirrhotic patients had a slower 2nd phase slope than non-cirrhotic patients (0.06 vs 0.18 log/wk, P < 0.02). None of genotype 1 cirrhotic patients had a 1st phase decline larger than 1 log (non-cirrhotic patients: 55%, P < 0.02). A similar trend toward a slower 2nd phase slope was observed in genotype 3 cirrhotic patients but the 1st phase slope decline was not different. Sustained viral response was higher in genotype 3 patients than in genotype 1 patients (72% vs 14%, P < 0.001) and in genotype 1 non-cirrhotic patients than in genotype 1 cirrhotic patients (19% vs 0%). A second phase decline slower than 0.3 log/wk was predictive of non-response in all groups.
  
  
  CONCLUSIONS
  Genotype 3 has faster early viral decline than genotype 1. Cirrhosis correlates with a slower 2nd phase decline and possibly with a lower 1st phase slope decline in genotype 1 patients.
authors.affiliation: Department of Gastroenterology, University of São Paulo, School of Medicine, São Paulo, Brazil.
authors.forename: Jose-Eymard
authors.initials: JE
authors.lastname: Medeiros-Filho
authors.forename: Isabel-Maria-Vicente-Guedes
authors.initials: IM
authors.lastname: de Carvalho Mello
authors.forename: Joao-Renato-Rebello
authors.initials: JR
authors.lastname: Pinho
authors.forename: Avidan-U
authors.initials: AU
authors.lastname: Neumann
authors.forename: Fernanda
authors.initials: F
authors.lastname: de Mello Malta
authors.forename: Luiz-Caetano
authors.initials: LC
authors.lastname: da Silva
authors.forename: Flair-Jose
authors.initials: FJ
authors.lastname: Carrilho
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D001938:Brazil; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D006526:Hepatitis C / Q000188:drug therapy*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007700:Kinetics; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000821:virology*; D012367:RNA, Viral / Q000097:blood; D012254:Ribavirin / Q000627:therapeutic use*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral; D012254:Ribavirin